Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma by Qian Zhao, Teng Wang, Huanhuan Wang, Cheng Cui, Wen Zhong, Diyi Fu, Wanlin Xi, Lu Si, Jun Guo, Ying Cheng, Hongqi Tian, Pei Hu

Get full text